This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Jan 31;380(5):497-498.

doi: 10.1056/NEJMc1816156.

CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma

Ranjana Advani¹, Jens-Peter Volkmer², Mark P Chao²

Affiliations

PMID: 30699313
DOI: 10.1056/NEJMc1816156

Comment

CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma

Ranjana Advani et al. N Engl J Med. 2019.

. 2019 Jan 31;380(5):497-498.

doi: 10.1056/NEJMc1816156.

Authors

Ranjana Advani¹, Jens-Peter Volkmer², Mark P Chao²

Affiliations

¹ Stanford University, Stanford, CA radvani@stanford.edu
² Forty Seven, Menlo Park, CA

PMID: 30699313
DOI: 10.1056/NEJMc1816156

No abstract available

PubMed Disclaimer

Comment on

CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
Valerius T, Rösner T, Leusen JHW. Valerius T, et al. N Engl J Med. 2019 Jan 31;380(5):496-7. doi: 10.1056/NEJMc1816156. N Engl J Med. 2019. PMID: 30702240 No abstract available.
CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
Li Y. Li Y. N Engl J Med. 2019 Jan 31;380(5):497. doi: 10.1056/NEJMc1816156. N Engl J Med. 2019. PMID: 30702241 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
Research Materials
- NCI CPTC Antibody Characterization Program